Quick answer
Cirrhosis replaces functioning liver tissue with fibrosis. The approach EHL Bio describes uses the patient's own multipotent stem cells injected directly into the hepatic artery so they can support regeneration of damaged liver tissue, with reported reductions in ascites volume and improved liver function. Using autologous cells also lowers immune rejection risk.
